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Abstract: The effects of cyclosporin A (CsA)
on rat pancreatic islet β and D cells and
plasma glucose levels at doses of 50 mg/kg
body weight applied for 20 days were
investigated. Fifteen Swiss Albino rats were
used as the study group and 5 were the
control group. Rat pancreatic islet β and D
cells were stained immunocytochemically by
anti-insulin
and
anti-somatostation
antibodies. β and D cells from 15 different
islets were evaluated qualitatively and
quantitatively. Plasma glucose changes were
also compared between the study and the
control group. The pancreas morphology was
found to be normal in both groups by light
microscopy. The difference between the

Introduction
Cyclosporin A (CsA), discovered in 1972 by Borel, has
rapidly become the most commonly used
immunosuppressive agent in clinical transplantation (18). It has also become a therapeutical alternative for
immune suppressive therapy in Type I diabetes, since
there is evidence that an autoimmune process directed
toward the insulin producing β cells may play a role in the
development of the disease (1, 4, 6, 7). The
immunosuppressive effect of CsA was mediated through
blocking of the precursor T cell in G0 or early G1 plase of
the cell cycle (1). CsA can exert hepatotoxic and
nephrotoxic effects related to dose and duration. It has
also been demonstrated that CsA accumulates in the
pancreas resulting in high localized tissue concentrations
(2, 3). Other side effects, usually mild, include tremors
(15%), hirsutism (12%), and gingival hyperplasia and
insulin metabolism are conflicting. Several in vitro studies
have shown that CsA has an adverse effect on islet β cell
function even with therapeutically recommended doses
and it impairs insulin synthesis and secretion. This has
resulted in hypoinsulinemia, glucose intolerance, and
hyperglycemia accompanied by marked decrease in
pancreatic islet insulin content or release (1-3, 6-8). In
contrast, some studies have suggested that CsA did not

numbers of β and D cells of pancreatic islets
among the groups was not statistically
significant. The staining intensity of islet β
cell cytoplasms was lighter in the CsA
administered rats. Plasma glucose levels of
CsA-exposed rats increased significantly
compared with the control group (p<0.05).
In concluson, pancreatic islets were not found
to be affected morphologically by CsA at the
light microscopic level. The present findings
show that CsA impairs the glucose
metabolism possibly due to β cell
dysfunction.
Key Words: Cyclosporin A, pancreatic islet, β
cell, D cell, glucose.

alter directly the insulin producing cells in vitro (4, 5).
There is also some information about the effect of CsA on
somatostatin producing D cells.
We performed an immunocytochemical investigation
to determine the effects of CsA on insulin producing β
cells and somatostatin producing D cells in rat pancreas
islets. Moreover, we aimed to detect the changes in
plasma glucose concentrations due to CsA.
Materials and Methods
This study was performed by the Internal Medicine
and Pathology Departments at the Experimental and
Clinical Investigations Center of Erciyes University,
Medical School. The principles of laboratory animal care
were followed. A group of 15 Swiss Albino rats were
used in the study. Another group of 5 rats were used as
controls. At the beginning of the study, after overnight
fasting, 1-2 ml heparinized blood samples were obtained
from the left jugular vein in aseptic conditions from both
gorups. The first group consisted of 15 rats receiving
daily subcutaneous injections of 50 mg/kg body weight of
CsA for 20 days. Following the last injection (day 20), the
rats were sacrified by dense ether anesthesia and average
1-2 ml blood samples were collected from the same site.
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The abdomen of each rat was opened and after dissecting
the muscles and intestines, pancreas was removed.
Pancreatic tissue was then fixed in 10% formalin. After
24 hours of fixation, the pancreas tissue was embedded
in paraffin wax. Sections 5 µm thick were cut and stained
with hematoxylin and eosin. Light microscopic
examination was performed.
For immunochemistry, same thickness, formalinefixed, and paraffin embedded sections were stained by
polyclonal antisera as anti-insulin (Insulin, polyclonal, cat
no: AGO29-5P, BioGenex Lab, San Ramon, CA, 94583,
USA) and anti-somatostatin (Somatostatin, polyclonal, cat
no: ARO42-5R, BioGenex Lab, San Ramon, CA94583,
USA). Insulin-immunoreactive β and somatostatinimmunoreactive D cells from 15 different areas of islets
were counted under a light microscope at 40x
magnification for the study and the control group. The
intensity of cytoplasmic immunostaining was determined
as “normal” or “light”. The number of cells stained
normal or lightly was also counted in both groups.
Fasting plasma glucose levels were measured by routine
biochemical methods at university hospital laboratories.
Statistical analysis. All results were expressed as
mean±SEM. The differences between CsA administered
and control rats were compared with the Mann-Whitney
U test and paired t test. A p value <0.05 was considered
statistically significant.

Table 2.

Numbers of somatostatin-immunoreactive cells in CsA
administered and control group in pancreatic islets.

Groups

n

Minimal-Maximal

Median

CsA
Control

15
5

180-264
199-223

230
211

u: 22.0, p>0.05.

In
immunostained
sections,
the
insulinimmunoreactive cells showed generally light
immunostaining in the CsA administered group (Figure 1)
but the cytoplasms in the control rats generally showed
normal staining (Figure 2). The number of islets with
lightly stained insulin-immunoreactive cells were more
than the islet numbers with normally stained cells in CsA
administered rats. This difference was not statistically
significant (Table 3).
Biochemical assay. On day 20, the mean fasting
plasma glucose levels of CsA administered rats were
significantly higher than plasma glucose concentrations
before CsA administration (198.87±16.8 mg/dl versus
107.40±10.3 mg/dl, p<0.05) (Table 4). No significant
change was found in the control group (106.72±10.8
versus 107.38±10.1).

Results
Morphological assay. The rat pancreatic islets
morphology of CsA administered rats and the control rats
had similar features to each other and were found to be
normal by light microscopic examination.
Immunocytochemical assays. The changes in the
number of insulin-immunoreactive cells in pancreatic
islets of CsA administered rats were not significantly
different from those in the control group (Table 1).
Similarly, numbers of the somatostatin-immunoreactive
cells in CsA group rats were not significantly different
from these in the control rats (Table 2).
Table 1.

Number of insulin-immunoreactive cells in CsA administered and control group in pancreatic islets.

Groups

n

Minimal-Maximal

Median

CsA
Control

15
5

445-635
489-574

515
497

u: 30.0, p>0.05.
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Figure 1.

The insulin-immunoreactive cells showed mostly light
immunostaining in the CsA administered group
(immunochemistry, 40x).

Discussion
We found no morphological changes in rat pancreas
islets compared with control rats under light microscopic
examination even at doses of CsA as high as 50 mg/kg for
20 days. At therapeutic doses (15 mg/kg), no
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organelles. They suggested that CsA induced a substantial
defect in granulogenesis.

Figure 2.

Mostly normally stained β cells in the control rats (immunochemistry, 40x).

Table 3.

Intensity of immunostaining of insulin-immunoreactive cells
in CsA administered and control group in pancreatic islets.
Normal
Median
Min-Max

Islet number
(n=15)
CsA
Control

6
10

3-7
9-12

Light
Median

Min-Max

9
5

8-12
3-6

u: 75.0, p>0.05u: 50.0, p>0.05
Table 4.

Plasma glucose concentrations in CsA administered rats
before and after study.

Time
Day0
Day20

n

mean±SEM (mg/dl)

15
15

107.40±10.3
198.87±16.8

t: 16.23, p<0.05.

morphological changes could be identified in the pancreas
at the light microscopic level (8). Ultrastructural studies
of the CsA exposed islet cells showed no signs of nuclear
pycnosis (1). Andersson et al. (1) reported that the
mitochondria and endoplasmic reticulum had not been
affected and the β cells were well granulated. These
findings were confirmed by Laube et al. (4) since in their
research electron micrographs of CsA-treated islets did
not differ from cultured control islets. In contrast, BaniSacchi et al. (2) observed different degrees of dilatation
of rough endoplasmic reticulum cistarnae and
enlargement of the Golgi apparatus in β cells, together
with a pronounced reduction in the number of secretory
granules. They noted that there were no apparent
morphological changes in the other cytoplasmic

We also could not find and significant difference
between the number of insulin-immunoreactive cells of
the pancreatic islets of CsA administered group and the
control group. No direct effect on β cells occurs
numerically. Therefore the mechanism of action has to be
due to drug-induced dysfunction. Indeed, studies have
revealed no β cell degeneration or cell death (2, 6-8). CsA
effects on insulin content and the secretion function were
determined in isolated pancreas incubations. Most of
these studies suggested that insulin content or secretion
function decreased due to CsA administration (1-3, 6-8).
It was found that CsA impairs islet β cell function and it
was suggested that the detrimental effect was located at
the level of protein biosynthesis and added that the
influence of CsA on the glucose recognition system could
not be excluded (1). The decrease in immunoreactive
insulin and glucose intolerance together with a reduction
in the number of secretory granules were related to
impairment in the intracellular transport of the hormone
from the sites of synthesis to the secretory granules
induced by CsA (2). The impaired carbonhydrate
tolerance was thought to be due to the marked reduction
of the pancreatic insülin reserve (3). Nielsen et al. (6)
reported that CsA has a direct inhibitory effect on insülin
release from human islets with a concomitant increase in
the residual insulin content. The same study also showed
that CsG inhibited insulin release, while CsD had no
consistent effects and the authors suggested that there is
a difference in immunosuppressive potency between
these analogues. Similar results were reported by
Robertson (7) showing that CsA inhibits glucose-induced
insulin secretion in a dose-response manner at
concentrations commonly found in blood. Total pancreatic
insulin was decreased to one third of the control after 5
weeks and after withdrawal of cyclosporin, impaired
glucose tolerance returned to normal within 2 weeks in
one study (8). These results were related to the inhibition
of insulin secretion and also possibly the inhibition of
synthesis since the plasma insulin levels were significantly
low.
In contrast, the results of some studies showed no
effects of CsA on the endocrin pancreas in vitro (4, 5).
Laube et al. (4) observed minimal changes even with very
high levels of CsA in short term effects. Exposure to long
term CsA resulted in a minimal decrease in insulin content
which was not accompanied by drastic changes in insulin
secretion. They assumed that CsA lead to minimal
functional changes in the endocrin pancreas even in toxic
concentrations. Another study demonstrated no reduction
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in the glucose-induced insulin secretion of rat islets (5).
Since they observed a slight increase in hormone release,
the authors concluded that CsA did not directly and
immediately alter the insulin-producing cells.
In
immunostained
sections,
the
insulinimmunoreactive cells generally showed a light
immunostaining in the CsA administered group but
normal staining of the cytoplasms of the control rats. This
staining difference was possibly due to a decrease in
cytoplasmic granules. We also demonstrated the glucose
intolerance-inducing effect of CsA in rats. When both
findings were interpreted together, we thought that CsA
may have caused a defect in granulogenesis. This result is
compatible with the suggestion of Bani-Sacchi et al. (2)
who assumed that the impairment in the secretory
processes of β cells was due to CsA.

We found no difference between the numbers of the
somatostatin-immunoreactive cells in the CsA group and
in the control rats. CsA did not seem to effect the
somatostatin producing cells, morphologically. In one
study, mean areas of somatostatin immunoeactivity
showed a significant increase (2). Glucagon content,
which we did not investigate in the present study, was
determined in several studies. Either glucagon content or
mean areas of glucagon immunoreactivity did not change
in some of these studies (2, 6). It was reported that the
glucagon content of islets was found to be decreased
significantly after 3 weeks administration of CsA (3).
In conclusion, the present data reveal that CsA impairs
glucose metabolism due to β cell dysfunction. We also
observed that CsA did not affect pancreatic islets
morphologically.
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